Neurol. pro Praxi, 2003; 5: 258-262

Léčba demence inhibitory cholinesteráz - bezpečnost a snášenlivost v praxi

doc. MUDr. Vladimír Pidrman Ph.D, prof. MUDr. Jaroslav Bouček CSc, MUDr. Klára Látalová
Psychiatrická klinika FN a LF UP, Olomouc

Keywords: Alzheimerova demence, inhibitory cholinesteráz, donepezil, rivastigmin, galantamin.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pidrman V, Bouček J, Látalová K. Léčba demence inhibitory cholinesteráz - bezpečnost a snášenlivost v praxi. Neurol. praxi. 2003;4(5):258-262.

Autoři podávají praktický pohled na léčbu demence inhibitory cholinesteráz. Oceňují terapeutický pokrok, který zavedení inhibitorů cholinesteráz - donepezilu, galantaminu a rivastigminu - přineslo. Nastiňují problémy, které mohou nastat v praxi, a to zejména v důsledku zásahu do cholinergního metabolizmu nebo v souvislosti s možnými interakcemi, a to interakcemi mezi inhibitory cholinesteráz a jinými podávanými léky, tak i inhibitory a přítomnými tělesnými nemocemi provázejícími často vyšší věk. Autoři uvádějí, že správný výběr léku a odpovídající monitorování rizikových veličin vede ke zvýšení komfortu jak nemocných, tak i personálu.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Auriacombe S, Pere JJ, Loria-Kanza, Vellas B. Efficacy and safety of rivastigmine in patiens with Alzheimer's disease who failed to benefit from treatment with donepezil. Current Medical research and opinion 2002; 3: 129-138. Go to original source... Go to PubMed...
    2. Bryant J, Clegg A, Nicholson T, et al. Clinical and cost-effectiveness of donepezil, rivastigmin and galantamin for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 2001; 5: 1-137. Go to original source... Go to PubMed...
    3. Corey-Bloom J, Anand R, Veach J, for the ENA-713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartate), a new acetylcholinesterase inhibitor, in patiens with mild to moderately severe Alzheimer's disease. Int J Geriart Psychofarmacol 1998; 1: 55-65.
    4. Doody RS, Stevens JC, Beck C, et al. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154-1166. Go to original source... Go to PubMed...
    5. Grossberg GT, Stehelin HB, Messina JC, Anand R, Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of mediacations. Int J Geriatr Psychiatry 2002; 15: 242-247. Go to original source...
    6. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. UCP Supplement June 2002; 12: 45-63.
    7. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41 (10): 719-739. Go to original source... Go to PubMed...
    8. Mesulam MM, Guillozet AL, Shaw P, et al. Preservation of cholinergic systems in AChE knockouts and the role of BChE in acetylcholine hydrolysis. Poster presented at 31 st Meeting of the Society for Neuroscience, San Diego, USA, 15 November 2001.
    9. Mesulam M, Guillozet AL, Shaw P, et al. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis. 2002; 9: 88-93. Go to original source... Go to PubMed...
    10. Nordberg A, Darreh-Shori T, Svensson A, et al. Acetylcholinesterase (AChe) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patoens following 12 months of rivastigmine treatment. J Neurol Sci 2001; 187 (Suppl 1): P0144.
    11. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with 6-month extension. The galantamine USA-1 Study Group. Neurology 2000; 54: 2261-2268. Go to original source... Go to PubMed...
    12. Rosler M, Anand R, Cicin-Sain A, et el. Efficacy and safety of rivastigmine in patiens with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-638. Go to original source... Go to PubMed...
    13. Reuben BD, Herr KA, Pacala JT, et al: Geriatrics at your fingertips. Blackwell Publishing, Inc., Malden, 2003, 240 p.
    14. Siek GC, Katz LS, Fishman EB, et al. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer's disease brain. Biol Psychiatry 1990; 27: 573-580. Go to original source... Go to PubMed...
    15. Schaltberg AF, Cole JO, DeBatista C. Manual of clinical psychopharmacology. American Psychiatric Publishing, Inc. Washington, DC, 2003, 700p.
    16. Vellas B, Inglis F, Potkin S, et al. Interim results from an international clinical trial with rivastigmine evaluating a 2-week titration rate in mild to severe Alzheimer's disease patients. Int J Geriatr Psychopharmacol 1998; 1: 140-144.
    17. Weinstock M. Selectivity of cholinesterase inhibition. CNS Drugs 1999; 12: 307-323. Go to original source...
    18. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patiens with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321: 1445-1449. Go to original source... Go to PubMed...
    19. Wilkinson DG, Passmore P, Smith R, et al. Comparison of the tolerability, ease of use and efficacy of donepezil and Exelon in Alzheimer's disease patients: a 12-week multinational study. Presented at the 53rd Annual Meeting of the American Academy of Neurology, Philadelphia, Pensylvania, 5-12 May 2001.
    20. Zurag EG. New treatments of alzheimer's disease: a review. A Drug Benefit Trends 2001; 13: 27-40.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.